TY - JOUR
T1 - Benefits of varenicline vs. bupropion for smoking cessation
T2 - a Bayesian analysis of the interaction of reward sensitivity and treatment
AU - Cinciripini, Paul M.
AU - Green, Charles E.
AU - Robinson, Jason D.
AU - Karam-Hage, Maher
AU - Engelmann, Jeffrey M.
AU - Minnix, Jennifer A.
AU - Wetter, David W.
AU - Versace, Francesco
N1 - Publisher Copyright:
© 2017, Springer-Verlag Berlin Heidelberg.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Rationale: We have shown that differences in the level of neural activation to stimuli associated with smoking vs. natural rewards, a biomarker related to reward sensitivity, predict treatment outcome. Objectives: This paper examined whether this biomarker moderates the impact of bupropion or varenicline on smoking cessation. Methods: Prior to treatment randomization, smokers (N = 180) in a placebo-controlled trial using bupropion and varenicline completed event-related potential recording (late positive potential, LPP) while viewing pleasant (P), cigarette (C)-related, and other pictures. We used Bayesian models to estimate the probability of interaction between treatment and the LPP for both efficacy and comparative effectiveness analyses. Results: Efficacy analysis showed that smokers with more neural activation to pleasant vs. cigarette-related stimuli (P > C) had a 98–99% chance of achieving greater abstinence than placebo (OR >1.00), using either medication from the end of treatment (EOT, primary outcome) through the 3-month follow-up. Relative to placebo, smokers with higher activation to cigarette-related vs. pleasant stimuli (C > P) had a 99% chance of increased benefit from varenicline at both time points (OR >1), but only 67 and 43% with bupropion at the EOT and 3-month follow-up, respectively. Comparative effectiveness analysis found that smokers with the C > P activation pattern had a 95–98% chance of benefit from varenicline vs. bupropion, while P > C smokers had a 50–58% chance of similar improvement with varenicline at the EOT and 3 months. Conclusions: Varenicline appears to be the treatment of choice for smokers with the C > P pattern of neural activation, while for those showing P > C, varenicline and bupropion have similar efficacy.
AB - Rationale: We have shown that differences in the level of neural activation to stimuli associated with smoking vs. natural rewards, a biomarker related to reward sensitivity, predict treatment outcome. Objectives: This paper examined whether this biomarker moderates the impact of bupropion or varenicline on smoking cessation. Methods: Prior to treatment randomization, smokers (N = 180) in a placebo-controlled trial using bupropion and varenicline completed event-related potential recording (late positive potential, LPP) while viewing pleasant (P), cigarette (C)-related, and other pictures. We used Bayesian models to estimate the probability of interaction between treatment and the LPP for both efficacy and comparative effectiveness analyses. Results: Efficacy analysis showed that smokers with more neural activation to pleasant vs. cigarette-related stimuli (P > C) had a 98–99% chance of achieving greater abstinence than placebo (OR >1.00), using either medication from the end of treatment (EOT, primary outcome) through the 3-month follow-up. Relative to placebo, smokers with higher activation to cigarette-related vs. pleasant stimuli (C > P) had a 99% chance of increased benefit from varenicline at both time points (OR >1), but only 67 and 43% with bupropion at the EOT and 3-month follow-up, respectively. Comparative effectiveness analysis found that smokers with the C > P activation pattern had a 95–98% chance of benefit from varenicline vs. bupropion, while P > C smokers had a 50–58% chance of similar improvement with varenicline at the EOT and 3 months. Conclusions: Varenicline appears to be the treatment of choice for smokers with the C > P pattern of neural activation, while for those showing P > C, varenicline and bupropion have similar efficacy.
KW - Bayesian statistics
KW - Bupropion
KW - Comparative effectiveness
KW - Smoking cessation
KW - Varenicline
UR - http://www.scopus.com/inward/record.url?scp=85014667873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014667873&partnerID=8YFLogxK
U2 - 10.1007/s00213-017-4580-2
DO - 10.1007/s00213-017-4580-2
M3 - Article
C2 - 28275830
AN - SCOPUS:85014667873
SN - 0033-3158
VL - 234
SP - 1769
EP - 1779
JO - Psychopharmacology
JF - Psychopharmacology
IS - 11
ER -